As COVID-19 continues to evolve, a new variant has emerged, catching the attention of scientists and health officials alike. This variant, known as XEC, has been detected in various parts of the world, including half of the United States. While it has yet to cause widespread concern, it raises important questions about the future of the pandemic and what we can expect in the coming months.What is the XEC Variant?XEC is a recombinant variant of SARS-CoV-2, which means it originated from the combination of two existing variants. Specifically, it is a sublineage of the omicron variant, formed by the recombination of KS.1.1 and KP.3.3, both of which are descendants of the JN.1 strain. Recombinant variants occur when an individual is infected by two different strains simultaneously, allowing their genetic material to mix and create a new variant.This new variant was first detected in Berlin in June 2024, and since then, it has spread rapidly across Europe, North America, and Asia. In the United States, XEC has been reported in at least 25 states, with New Jersey, California, and Virginia reporting the highest number of cases. While its presence is growing, XEC has yet to outcompete other dominant strains such as KP.3.1.1, which currently accounts for over half of the COVID-19 cases in the U.S.The rise of XEC has garnered attention from variant trackers, particularly in Europe, where the variant has been spreading at a fast rate. According to experts, XEC is currently the fastest-growing COVID-19 variant in countries like Germany and Denmark. This rapid rise has led some to speculate that XEC may become the dominant strain in the U.S. and other regions by the fall and winter of 2024.However, the overall public health concern remains relatively low at this stage. Health officials, including those at the Centers for Disease Control and Prevention (CDC), have not raised alarms over XEC, unlike previous variants that exhibited more significant genetic mutations. As a recombinant of two closely related strains, XEC appears to behave similarly to other omicron subvariants in terms of transmissibility and clinical outcomes.COVID XEC Variant Transmissibility and SpreadAs with many other variants of SARS-CoV-2, XEC spreads primarily through respiratory droplets when an infected individual talks, coughs, or sneezes. Like its predecessors, it is considered highly contagious, and the rapid rise of cases in multiple countries suggests it can spread quickly under favorable conditions.Nevertheless, it is still too early to predict whether XEC will become the dominant strain globally. Experts like Dr. William Schaffner of Vanderbilt University Medical Center and Dr. Andrew Pekosz of Johns Hopkins Bloomberg School of Public Health note that XEC shares many characteristics with previous omicron variants, including its ability to spread efficiently. Still, there are no immediate "alarm bells" to suggest that this variant will cause more severe illness or escape immunity to a significant degree.Will XEC Cause a Fall Surge in US?In the U.S., the 2024 summer wave of COVID-19 infections has been more prolonged than expected, but it is now beginning to wane. However, as respiratory virus season approaches, health experts are keeping a close eye on the potential for a winter surge in cases, which could be driven by variants like XEC.Historically, COVID-19 cases have peaked in the winter months as people spend more time indoors, increasing the likelihood of transmission. While it is unclear how severe this year's winter wave will be, the CDC anticipates a rise in cases peaking in mid-January 2025.Dr. Eric Topol, a physician-scientist and director of the Scripps Research Translational Institute, has suggested that XEC could be the next major variant to "get legs" and drive a wave of infections in the coming months. Still, much remains uncertain, including whether XEC will outcompete other variants, how large the winter surge might be, and whether this variant will lead to more severe illness.Symptoms OF XEC VariantAs of now, there is no evidence to suggest that XEC causes different or more severe symptoms compared to other circulating COVID-19 variants. Common symptoms of COVID-19, including fever, cough, fatigue, and loss of taste or smell, are likely to remain consistent among those infected with XEC.Regarding vaccine effectiveness, the CDC has stated that this fall's updated COVID-19 vaccines are expected to provide protection against circulating variants, including XEC. These vaccines have been updated to target the KP.2 strain, which is closely related to XEC. The Food and Drug Administration (FDA) has also expressed confidence in the effectiveness of the updated vaccines.While it remains unclear how XEC will affect vaccine performance, experts are optimistic that the vaccines, along with treatments, will continue to be effective against all current COVID-19 strains, including XEC. As always, the CDC recommends that Americans receive their COVID-19 vaccines to ensure optimal protection during the upcoming respiratory virus season.Is XEC More Contagious Than Other Variants?Though there is still limited data on the XEC variant, early observations suggest that it may have the potential to be more transmissible than some of the currently circulating strains. The variant has already shown notable growth in countries like Germany, where it is spreading faster than other strains. However, whether it will surpass other dominant variants, such as KP.3.1.1 (also known as "DeFLuQE"), remains unclear.XEC possesses a mutation in its spike protein, the part of the virus responsible for binding to human cells, which may explain its rapid transmission. As with other Omicron subvariants, XEC is primarily spread through respiratory droplets when an infected person talks, coughs, or sneezes. While experts are monitoring its spread closely, they have not yet sounded alarm bells over its potential to outcompete other variants.XEC is a new recombinant variant of COVID-19 that has emerged in several countries, including the U.S. While it has not yet triggered widespread concern, its rapid rise warrants close observation as we head into the winter months. For now, the best course of action is to follow public health guidelines, stay informed about new developments, and ensure that vaccinations are up to date.